Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation

Marcela Haasova,1* Tristan Snowsill,1 Tracey Jones-Hughes,1 Louise Crathorne,1 Chris Cooper,1 Jo Varley-Campbell,1 Ruben Mujica-Mota,1 Helen Coelho,1 Nicola Huxley,1 Jenny Lowe,1 Jan Dudley,2 Stephen Marks,3 Chris Hyde,1 Mary Bond1 and Rob Anderson1

1Peninsula Technology Assessment Group (PenTAG), Evidence Synthesis & Modelling for Health Improvement, University of Exeter, Exeter, UK
2Department of Paediatric Nephrology, Bristol Royal Hospital for Children (University Hospitals Bristol NHS Foundation Trust), Bristol, UK
3Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

*Corresponding author

Declared competing interests of authors: We would like to acknowledge that Stephen Marks received grants from Astellas and Novartis for immunosuppressive randomised controlled studies in paediatric renal transplant recipients during the conduct of the study. In addition, Jan Dudley was a member of an expert review panel in January 2008 and developed consensus recommendation on the optimal use of CellCept® (Roche Products) in paediatric renal transplantation and received an honorarium for Roche for this work.

Published August 2016
DOI: 10.3310/hta20610

Scientific summary

Immunosuppressive therapy for kidney transplantation
Health Technology Assessment 2016; Vol. 20: No. 61
DOI: 10.3310/hta20610

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Chronic kidney disease in childhood leads to lifelong health complications. A long-term progression of irreversible decline in kidney function to end-stage renal disease will require renal replacement therapy (kidney transplant, haemodialysis or peritoneal dialysis) for a child or adolescent to survive. The preferred option is kidney transplantation (transfer of a healthy kidney from a donor to a recipient). Kidneys for transplantation may be obtained via living donation (related or unrelated), donation after brain death or donation after circulatory death. Between April 2013 and March 2014, 125 kidney transplant operations were performed on children and adolescents in the UK.

Following kidney transplantation in children and adolescents, major clinical concerns are acute kidney rejection, graft loss and growth. Acute kidney rejection occurs when the immune system attempts to destroy the graft. Immunosuppressive therapy is then implemented to reduce the risk of kidney rejection and prolong graft survival. Immunosuppression comprises induction and maintenance therapy; induction involves powerful antirejection drugs taken at the time of transplantation, when the risk of rejection is highest, and maintenance drugs are less powerful and are used as both initial and long-term therapy.

Objectives

To review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab (BAS) (Simulect,® Novartis Pharmaceuticals) and rabbit antihuman thymocyte immunoglobulin (r-ATG) (Thymoglobuline,® Sanofi) as induction immunosuppressive therapy and immediate-release tacrolimus (TAC-IR) [Adopt® (Sandoz); Capexion® (Mylan); Modigraf® (Astellas Pharma); Perixis® (Accord Healthcare); Prograf® (Astellas Pharma); Tacni® (Teva); Vivadex® (Dexcel Pharma)]; prolonged-release tacrolimus (TAC-PR) (Advagraf,® Astellas Pharma); belatacept (BEL) (Nulojix,® Bristol-Myers Squibb); mycophenolate mofetil (MMF) [Arzip® (Zentiva), CellCept® (Roche Products), Myfenax® (Teva), generic MMF is manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy’s Laboratories, Mylan, Sandoz and Wockhardt], mycophenolate sodium (MPS) (Myfortic,® Novartis Pharmaceuticals), sirolimus (SRL) (Rapamune,® Pfizer), everolimus (EVL) Certican,® Novartis Pharmaceuticals) as maintenance immunosuppressive therapy in children and adolescents undergoing renal transplantation.

Methods

Clinical effectiveness systematic review

Bibliographic literature searching was conducted on 14 April 2014 (updated 7 January 2015). The searches for individual studies [randomised controlled trials (RCTs) and controlled clinical trials] took the following form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under review) AND (a study design limited to RCTs or controlled trials). Literature searches were not restricted to child or young adult populations, primarily to preserve the sensitivity of the searches. In order to update the previous assessment by Yao et al. [Yao G, Albon E, Adi Y, Milford D, Bayliss S, Ready A, et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess 2006;10(49)] the searches were date limited (2002–current). The following databases were searched: MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid), EMBASE (via Ovid), Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web of Science (via Institute for Scientific Information (ISI) – including conference proceedings). In addition, the following trials registries were hand-searched in January 2015:
Current Controlled Trials, ClinicalTrials.gov, Food and Drug Administration website, European Medicines Agency website (European Public Assessment Reports).

Separate searches were undertaken to identify systematic reviews of RCTs and non-randomised controlled studies, run from database inception in MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations (via Ovid), EMBASE (via Ovid), Cochrane Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA) (The Cochrane Library via Wiley Online Library) and Health Management Information Consortium (via Ovid). These searches took the following form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under review) AND (a pragmatic limit to systematic reviews).

Records and subsequent full papers were dual screened for inclusion independently by two researchers. Disagreements were resolved by discussion, with involvement of a third reviewer. Data were extracted if appropriate and quality appraisal conducted based on Centre for Reviews and Dissemination (CRD) guidance.

Data were tabulated and discussed in a narrative review and, when data permitted, meta-analysis was conducted. Estimates of overall treatment effect and assessment of heterogeneity were performed using a random-effects model. Odds ratios (ORs) and mean differences were calculated (for binary and continuous data, respectively).

**Cost-effectiveness systematic review**

Bibliographic literature searching was conducted on 8 April 2014 (updated 15 January 2015) in MEDLINE (via Ovid), EMBASE (via Ovid), NHS Economic Evaluation Database (via Wiley Online Library), Web of Science (via ISI – including conference proceedings), Health Economic Evaluations Database (HEED) (via Wiley Online Library) and EconLit (EBSCO host). The searches took the following form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under review) AND (a costs or economic literature search filter). The search was date limited 2002–current in line with the previous assessment, but was not limited by language or to human-only studies.

Records were dual screened by two reviewers (disagreements resolved by discussion). Studies meeting the criteria for inclusion were assessed by one reviewer using the Evers checklist. Studies were based on decision models were quality assessed using the Philips checklist.

Economic studies were extracted, summarised and synthesised using tabulated data and narrative synthesis.

**Appraisal of company submissions**

The appraisal of company submissions focused on their model-based economic analyses. Their systematic reviews were primarily assessed to establish whether or not any includable RCTs were missed by our searches. None were found.

**Assessment group economic model**

A new economic model was developed to address the decision problem in a cost–utility analysis. A discrete time state transition model (semi-Markov) was employed in which transition probabilities were dependent on age and time since initial transplantation. A cycle length of one-quarter year was used and transitions were assumed to occur mid-cycle. A time horizon of 50 years was adopted. Costs were included from a NHS and Personal Social Services perspective. Health effects were measured in quality-adjusted life-years (QALYs) and calculated by assuming health state-specific utility decrements from a baseline utility, which was age-dependent and derived from the Health Survey for England (Health and Social Care Information Centre. *Health Survey for England – 2012*. London: Health and Social Care Information Centre; 2013). Costs and QALYs were discounted at 3.5% per annum and costs were inflated as necessary to 2014/15 prices.
**Model structure**

Kidney transplant recipients were assumed to be in one of three health states at any time: *functioning graft* (not dependent on dialysis), *graft loss* (dialysis dependent) or *death*. In addition to these health states, for each regimen the incidence of acute rejection (AR), cytomegalovirus (CMV) infection, dyslipidaemia and new-onset diabetes mellitus after transplantation (NODAT) were estimated, with corresponding costs (one-off for AR and CMV infection; ongoing for dyslipidaemia and NODAT). NODAT was also associated with a utility decrement. The incidences of AR and NODAT (and graft function after 12 months) were used as surrogate determinants of graft survival and the rate of death with functioning graft (DWFG) (NODAT only).

Up to three retransplantations were modelled, which could take place from the *graft loss* state. Pre-emptive retransplantation was also modelled for the initial graft, allowing retransplantation from the first *functioning graft* state. Kidney transplant recipients would transition to the next *functioning graft* state if retransplantation was successful or to the next *graft loss* state if it was unsuccessful.

**Results**

**Clinical effectiveness systematic review**

Three RCTs are included in the clinical effectiveness systematic review: one new RCT and two RCTs from the previous assessment.

Four non-RCTs are included in our review, all of which were also included in the previous assessment by Yao et al. (2006).

**Induction therapy**

Two RCTs of induction therapy evaluating BAS in children and adolescents were identified in the review. No RCTs were identified that evaluated r-ATG in children and adolescents. No non-RCTs in the child and adolescent population evaluated induction therapies.

We found no significant difference in survival, graft loss, graft function and incidences of biopsy-proven acute rejection (BPAR) and time to BPAR between BAS and placebo (PBO)/no induction.

The results of the current review are similar to the previous HTA (Yao et al. 2006).

**Maintenance therapy**

One RCT of maintenance therapy in children and adolescents was identified, evaluating tacrolimus (TAC) compared with ciclosporin (CSA). No RCTs were identified for the other maintenance treatments.

Three non-RCTs evaluating MMF [compared with azathioprine (AZA)] in children and adolescents were identified. One non-RCT compared TAC + AZA with CSA + MMF. No non-RCTs were identified for the other maintenance treatments.

From the RCTs, we found no significant difference in survival or graft loss between TAC and CSA. However, a significantly higher graft function [mean estimated glomerular filtration rate (eGFR) of 71.5 (standard deviation 22.9) ml/minute/1.73 m² in TAC vs. mean eGFR of 53.0 (21.6) ml/minute/1.73 m² in CSA, t-test = 4.03; p < 0.01 at 4-year follow-up] and less BPAR [OR 0.29, favours TAC, 95% confidence interval (CI) 0.15 to 0.57 at 6-month follow-up] was found in TAC compared with CSA.
The results of the current review for survival, graft function and BPAR are similar to the previous HTA. However, the child and adolescent RCT evidence identified in the previous HTA review concluded that TAC lowered graft loss at 2- and 4-year follow-up. The difference in these results is because we excluded graft loss due to death from all analyses to avoid double counting with another key outcome (mortality) and because death-censored graft survival is a well-established clinical outcome (to which DWFG is intrinsically related). After the removal of graft loss due to death from the analyses, the evidence from the RCT suggested statistically non-significant lower graft loss with TAC compared with CSA (OR 0.41, 95% CI 0.16 to 1.00, and OR 0.43, 95% CI 0.18 to 1.01 at 2 and 4 years' follow-up, respectively).

**Adverse events**

More infections were found in children treated with BAS than those treated with PBO (OR 2.23, favours PBO; 95% CI 1.03 to 4.68) and Grenda et al. (Grenda R, Watson A, Vondrak K, Webb NJ, Beattie J, Fitzpatrick M, et al. A prospective, randomized, multicenter trial of TAC-based therapy with or without basiliximab in pediatric renal transplantation. *Am J Transplant* 2006;6:1666–72) found that toxic nephropathy and abdominal pain was higher with BAS compared with no induction (*p* = 0.03 and *p* = 0.02, respectively). In one RCT, no statistically significant differences were found between TAC and CSA for a range of adverse events. In addition, there were no statistically significant differences identified between MMF and AZA, or between TAC + AZA and CSA + MMF, in the non-randomised evidence.

**Cost-effectiveness systematic review**

Only one previous cost-effectiveness study of immunosuppressive regimens in children and adolescents was identified. The study evaluated the cost-effectiveness of adding BAS induction to maintenance therapy with TAC or CSA combined with AZA and corticosteroids (CCSs). The study also compared CSA with TAC when given in combination with AZA and CCSs, and, separately, MMF versus AZA as part of the triple therapy containing CSA and CCSs.

The analysis was conducted using a Markov model of a cohort with starting age ranging between 3 and 13 years and a 10-year horizon, and found that BAS induction resulted in higher costs and more QALYs than no induction in both the TAC and CSA containing regimens. TAC was found to have a base-case incremental cost-effectiveness ratio (ICER) (incremental cost per QALY) of £145,000/QALY relative to CSA, while MMF had an ICER of £195,000/QALY relative to AZA when given as part of a CSA-containing triple therapy. The sensitivity analysis showed that these results were subject to a high degree of uncertainty.

**Analyses based on randomised controlled trial evidence in children and adolescents**

**Base-case analysis**

Compared with no induction, BAS was predicted to be cost-effective at £20,000–30,000 per QALY when used with TAC and AZA [based on Grenda et al. (2006), BAS was dominant], but not when used with CSA and MMF [based on Offner et al. (2008), BAS was dominated].

Based on Trompeter et al. (Trompeter R, Filler G, Webb NJA, Watson AR, Milford DV, Tyden G, et al. Randomized trial of tracolimus versus cyclosporin microemulsion in renal transplantation. *Pediatric Nephrology* 2002;17:141–9), TAC (when used with AZA) was predicted to be cost-effective at £20,000–30,000 per QALY versus CSA (TAC was dominant).

**Scenario analyses**

Results were robust to removal of the surrogate relationship between AR and graft survival and/or to assuming weight would follow the ninth centile for age instead of the median.
Analyses based on randomised controlled trial evidence in adults

Base case
In the base-case deterministic and probabilistic analyses, BAS, TAC, MMF (only when used with CSA) and AZA (only when used with TAC) were predicted to be cost-effective at £20,000–30,000 per QALY. When all regimens were simultaneously compared, only BAS + TAC + AZA was cost-effective at £20,000–30,000 per QALY.

Scenario analyses
Results were robust to removal of the surrogate relationship between AR and graft survival. When it was assumed that weight would follow the ninth centile for age instead of the median, BAS and TAC were still predicted to be cost-effective at £20,000–30,000 per QALY. However, when used with BAS, MPS was predicted to be cost-effective at £30,000 per QALY (ICER £27,000 per QALY) and MMF was predicted to be cost-effective at £20,000 per QALY.

Limitations
The number of included randomised trials is low (also comparative non-RCTs may have been missed); only RCT evidence evaluating BAS and TAC and non-RCT evidence on the use of TAC and MMF was identified. In addition, no studies reporting on quality of life, adherence, growth or supporting the subgroup analyses specified in the review protocol were identified. Significantly, cost-effectiveness analyses comparing all interventions rely on effectiveness estimates from the adult RCTs (which may or may not generalise to children and adolescents). Finally, some of the newer immunosuppressive drugs, such as EVL and SRL, would normally be given to children and adolescents after an initial maintenance therapy that consists of more conventional drugs. This makes it challenging to compare the clinical effectiveness of such regimens because only children and adolescents who are well maintained on their initial maintenance therapy would be given such drugs.

Conclusions
There is limited high-quality evidence for the effectiveness of immunosuppressive agents in children and adolescents. A RCT comparing TAC with CSA demonstrated that TAC resulted in statistically significant improvements in graft function and AR. No other outcomes in that RCT or the other two included RCTs were statistically significant.

Based on effectiveness estimates from the adult population, BAS and TAC are cost-effective at a threshold of £20,000–30,000 per QALY in all considered combinations, while MMF is cost-effective only if used with CSA. Effectiveness estimates in children and adolescents are only available for BAS and TAC. Based on these, TAC (used with AZA and compared with CSA) is cost-effective at £20,000–30,000 per QALY, whereas cost-effectiveness results for BAS are mixed.

Implications for health care
BAS, TAC, MMF and AZA are all used regularly in the NHS. It is not clear whether or not changes to induction agents used in the NHS would significantly affect costs. However, replacing TAC with TAC-PR, SRL, BEL or CSA would likely result in increased costs.

It is possible that replacing MMF with AZA (when used with TAC) will result in reduced costs, while it is likely that replacing these with SRL, EVL or MPS would increase costs.
Recommendations for research

High-quality primary effectiveness research in children and adolescents is needed. Potentially, the UK Renal Registry could form the basis for a prospective study. This may require collection of some information not currently held, but could include health-related quality of life and growth measurements. In addition, given the perceived importance of adherence to immunosuppression in this population, an objective and practical measure of adherence is needed. Furthermore, a systematic review of non-RCTs is recommended.

Study registration

The protocol for the HTA is available on National Institute for Health and Care Excellence (NICE) website [NICE. PROTOCOL: Immunosuppressive therapy for kidney transplantation in children and adolescents (review of technology appraisal guidance TA99). London: NICE, 2014]. This study is also registered as PROSPERO CRD42014013544.

Funding

Funding for this study was provided by the HTA programme of the National Institute for Health Research.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 09/119/01. The protocol was agreed in July 2014. The assessment report began editorial review in May 2015 and was accepted for publication in October 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Haasova et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the EME Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Director, Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk